EyePoint Cuts Half of Staff After Failed Drug Trial
The company is terminating its age-related macular degeneration drug development to refocus on other treatments.
Updated on Oct. 20, 2026 in Biotech
Live Poll
Do you trust pharmaceutical companies to manage their drug development and workforce decisions responsibly?
EyePoint is reducing its total workforce by 53 percent and ending trials of its experimental drug Duravyu for age-related macular degeneration. This move follows a late-stage clinical trial where the drug failed to show efficacy comparable to Eylea.
Why it matters
The company aims to slash operating costs by $30 million annually to stabilize its finances after trial outcomes missed primary efficacy goals. Shifting development focus to diabetic macular edema is intended to sustain the business long-term.
EyePoint reported $9 million in severance charges associated with the headcount reduction. The drug Duravyu failed to meet its primary efficacy goals when benchmarked against Eylea during late-stage trials.
The players
EyePoint
This is a biotechnology company focused on developing pharmaceutical products to treat eye diseases.
The details
The decision comes after Duravyu failed to prove as effective as the competitor medicine Eylea in preserving eyesight during trials that missed their main objective in August 2026. EyePoint will now narrow its research and development priorities to focus on treatments for diabetic macular edema.
Timeline
February 27, 2026: EyePoint reported having 214 full-time U.S. staff.
August 2026: The Duravyu clinical trial failed to meet its primary goal.
October 19, 2026: EyePoint announced the workforce reduction and trial termination.
Late 2027: Results are expected for diabetic macular edema trials.
The Tech Race
This development underscores the volatility of biotech R&D where drug candidates are frequently measured against established market leaders like Eylea. Failing to clear these performance hurdles often forces companies to abandon major projects and undergo significant structural downsizing.
The cancellation of these trials means that the drug Duravyu will not become an available treatment option for patients with age-related macular degeneration. The significant downsizing also suggests a period of transition and operational instability within the company.
The takeaway
Biotech firms often rely on a narrow pipeline of drug candidates, making the failure of a single late-stage trial a significant financial risk. Investors and patients should monitor how the company reallocates its remaining resources toward its diabetic macular edema program.
What happens next
EyePoint is scheduled to release clinical trial results for its diabetic macular edema treatment in late 2027.
Further reading
For more context on how clinical trial failures influence industry trends, visit United States Biotech.
Live Poll
Do you trust pharmaceutical companies to manage their drug development and workforce decisions responsibly?
